Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 open-label study of E/C/F/TAF in virologically suppressed HIV-1 infected adolescents
2014-002673-11Phase 2
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoint: Incidence of treatment-emergent SAEs and all treatment-emergent AEs.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-002673-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002673-11.